Ascendis Pharma A/S (NASDAQ:ASND) SVP Mads Bodenhoff Sells 3,000 Shares

Ascendis Pharma A/S (NASDAQ:ASND) SVP Mads Bodenhoff sold 3,000 shares of Ascendis Pharma A/S stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total value of $810,570.00. Following the completion of the transaction, the senior vice president directly owned 3,000 shares in the company, valued at $810,570. This represents a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Ascendis Pharma A/S Price Performance

ASND stock opened at $260.81 on Thursday. Ascendis Pharma A/S has a one year low of $186.05 and a one year high of $282.15. The firm has a 50-day moving average of $257.91 and a two-hundred day moving average of $241.71. The firm has a market capitalization of $16.27 billion, a PE ratio of 20.23 and a beta of 0.35. The company has a current ratio of 2.99, a quick ratio of 2.32 and a debt-to-equity ratio of 0.27.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.68). Ascendis Pharma A/S had a net margin of 70.99% and a return on equity of 32.54%. The firm had revenue of $387.22 million for the quarter, compared to analyst estimates of $376.75 million. On average, analysts forecast that Ascendis Pharma A/S will post 5.15 earnings per share for the current year.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of large investors have recently bought and sold shares of the business. Advisory Services Network LLC bought a new position in Ascendis Pharma A/S during the third quarter valued at about $26,000. Arax Advisory Partners raised its stake in shares of Ascendis Pharma A/S by 212.2% in the 4th quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 104 shares in the last quarter. Leonteq Securities AG acquired a new stake in Ascendis Pharma A/S in the 4th quarter worth approximately $36,000. Caitong International Asset Management Co. Ltd bought a new stake in Ascendis Pharma A/S during the fourth quarter worth approximately $42,000. Finally, Global Retirement Partners LLC grew its holdings in Ascendis Pharma A/S by 111.9% during the fourth quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 113 shares during the last quarter.

Wall Street Analysts Forecast Growth

ASND has been the subject of several research analyst reports. BMO Capital Markets reissued an “outperform” rating on shares of Ascendis Pharma A/S in a research note on Thursday. UBS Group set a $345.00 price target on shares of Ascendis Pharma A/S in a report on Monday, August 31st. Stifel Nicolaus dropped their price objective on shares of Ascendis Pharma A/S from $328.00 to $326.00 and set a “buy” rating on the stock in a research note on Monday, August 31st. Royal Bank Of Canada lifted their target price on shares of Ascendis Pharma A/S from $280.00 to $290.00 and gave the company an “outperform” rating in a research note on Friday, August 14th. Finally, Bank of America dropped their price target on shares of Ascendis Pharma A/S from $306.00 to $304.00 and set a “buy” rating on the stock in a research note on Monday, August 31st. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $310.05.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company uses its proprietary TransCon technology platform to design long-acting medicines intended to improve the effectiveness, convenience, and tolerability of established treatments.

Ascendis’ marketed products include Skytrofa (lonapegsomatropin-tcgd), a long-acting growth hormone approved for the treatment of growth hormone deficiency in children, and Yorvipath (palopegteriparatide), a hormone replacement therapy for adults with hypoparathyroidism.